Equities

AstraZeneca PLC

AZN:LSE

AstraZeneca PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)14,104.00
  • Today's Change124.00 / 0.89%
  • Shares traded3.06m
  • 1 Year change19.67%
  • Beta0.8573
Data delayed at least 20 minutes, as of Feb 06 2026 16:33 GMT.
More ▼

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2024202420232022
ASSETS
Cash And Short Term Investments5,6545,9626,405
Total Receivables, Net13,09411,9359,923
Total Inventory5,2885,4244,699
Prepaid expenses1,7371,6171,329
Other current assets, total54116237
Total current assets25,82725,05422,593
Property, plant & equipment, net11,64710,5029,449
Goodwill, net21,02520,04819,820
Intangibles, net37,17738,08939,307
Long term investments1,9001,6771,142
Note receivable - long term574529592
Other long term assets18222874
Total assets104,035101,11996,483
LIABILITIES
Accounts payable3,6403,2672,550
Accrued expenses8,2838,8618,303
Notes payable/short-term debt330515350
Current portion long-term debt/capital leases2,3464,8855,192
Other current liabilities, total13,26713,0149,898
Total current liabilities27,86630,54226,293
Total long term debt27,61923,22223,690
Total debt30,29528,62229,232
Deferred income tax3,3052,8442,944
Minority interest852321
Other liabilities, total4,3745,3456,498
Total liabilities63,24961,97659,446
SHAREHOLDERS EQUITY
Common stock388388387
Additional paid-in capital35,22635,18835,155
Retained earnings (accumulated deficit)5,1723,5671,495
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity40,78639,14337,037
Total liabilities & shareholders' equity104,035101,11996,483
Total common shares outstanding1,5511,5501,550
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.